Tenecteplase for Acute Non–Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke

Does intravenous tenecteplase administered 4.5 to 24 hours after onset improve clinical outcomes among patients with non–large vessel occlusion acute ischemic stroke and salvageable brain tissue?This randomized clinical trial that included 566 patients found that 43.6% of patients receiving tenecteplase and 34.2% of patients receiving standard medical treatment achieved an excellent functional outcome (measured by a modified Rankin Scale score of 0 or 1) at 90 days. This resulted in a risk ratio of 1.28, a difference that was statistically significant.Findings from this study support intravenous tenecteplase given 4.5 to 24 hours after stroke onset for patients with acute non–large vessel occlusion and salvageable brain tissue.

Corresponding Author: Junwei Hao, MD, PhD, Department of Neurology, Xuanwu Hospital Capital Medical University, National Center for Neurological Disorders, 45 Changchun St, Beijing, China (haojunwei@vip.163.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.